Article info

Download PDFPDF

Prevention of hepatic encephalopathy by administration of rifaximin and lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt (TIPS): a multicentre randomised, double blind, placebo controlled trial (PEARL trial)

Authors

  1. Correspondence to Dr R B Takkenberg; r.b.takkenberg{at}amsterdamumc.nl
View Full Text

Citation

de Wit K, Schaapman JJ, Nevens F, et al
Prevention of hepatic encephalopathy by administration of rifaximin and lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt (TIPS): a multicentre randomised, double blind, placebo controlled trial (PEARL trial)

Publication history

  • Received August 28, 2020
  • Revised November 12, 2020
  • Accepted November 26, 2020
  • First published December 28, 2020.
Online issue publication 
December 28, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.